Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00061828 · ClinicalTrials.gov registry record
A Prospective Database of Infants With Cholestasis
A clinical trial of Biliary Atresia, sponsored by Arbor Research Collaborative for Health.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 16
- Study locations
NCT00061828: Recruiting study of Biliary Atresia, sponsored by Arbor Research Collaborative for Health.
NCT00061828 is a study of Biliary Atresia that is actively recruiting participants, run by Arbor Research Collaborative for Health. The registered enrollment target is 1,000 participants, above the 432-participant average among 7 other Biliary Atresia trials with a reported enrollment target (131% higher). The trial reports 16 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00061828, a study of Biliary Atresia, is actively recruiting participants, sponsored by Arbor Research Collaborative for Health.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 16
- Study locations
Study Summary
Biliary atresia, idiopathic neonatal hepatitis, and specific genetic cholestatic conditions are the most common causes of jaundice and hyperbilirubinemia that continue beyond the newborn period. The long term goal of the Childhood Liver Disease Research Network (ChiLDReN) is to establish a database of clinical information and plasma, serum, and tissue samples from cholestatic children to facilitate research and to perform clinical, epidemiological and therapeutic trials in these important pediatric liver diseases.
Primary Outcome
disease progression defined by transplant date, date of death, worsening liver function, and complications related to worsening liver function
Conditions Studied
Study Locations (16)
California
- Children's Hospital Los Angeles - Los Angeles
- University of California - San Francisco
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- UPMC Children's Hospital of Pittsburgh - Pittsburgh
Colorado
- Children's Hospital Colorado - Aurora
Georgia
- Children's Healthcare of Atlanta - Emory University - Atlanta
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Indiana
- Riley Hospital for Children - Indianapolis
Maryland
- Johns Hopkins School of Medicine - Baltimore
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2004-04-21 |
| Est. Completion | 2029-05-31 |
What NCT00061828 shows while recruiting
NCT00061828 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 432-participant average among 7 other Biliary Atresia trials with a reported enrollment target (131% higher).
The record links to 1 condition, with Biliary Atresia appearing as the primary indexed condition, and to 0 interventions.
NCT00061828 lists 16 locations in 14 states (California, Pennsylvania, Colorado).
Frequently Asked Questions
What is clinical trial NCT00061828 about?
NCT00061828 is a clinical study titled "A Prospective Database of Infants With Cholestasis". Biliary atresia, idiopathic neonatal hepatitis, and specific genetic cholestatic conditions are the most common causes of jaundice and hyperbilirubinemia that continue beyond the newborn period. The long term goal of the Childhood Liver Disease Research Network (ChiLDReN) is to establish a database ...
What is the current status of trial NCT00061828?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2004-04-21. Estimated completion is 2029-05-31.
What conditions does trial NCT00061828 study?
This clinical trial studies the following conditions: Biliary Atresia.
Who is sponsoring clinical trial NCT00061828?
This trial is sponsored by Arbor Research Collaborative for Health, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00061828 being conducted?
This trial has 16 study locations across California, Colorado, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Biliary Atresia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mapping Disease Pathways for Biliary Atresia
RECRUITING
-
Biliary Atresia Research Network Northeast
RECRUITING
-
Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
RECRUITING · Phase 1
-
Biliary Atresia Study in Infants and Children
RECRUITING
-
The Use of Near-Infrared Fluorescence Cholangiography With Indocyanine Green (ICG) in the Work Up of Neonatal Cholestasis
RECRUITING · Early Phase 1
-
Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI